Publications

1. Chen R, Tang L, Melendy T, Yang L, Goodison S, Sun Y. Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States. Cancer Res Commun. 2024 Oct 1; 4 (10):2783-2798
   View PubMed
2. Yang L, Chen R, Melendy T, Goodison S, Sun Y. Identifying Significantly Perturbed Subnetworks in Cancer Using Multiple Protein-Protein Interaction Networks. Cancers (Basel). 2023 Aug 14; 15 (16)
   View PubMed
3. Murakami K, Furuya H, Hokutan K, Goodison S, Pagano I, Chen R, Shen CH, Chan MWY, Ng CF, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, Wang Z, Yu H, Rosser CJ. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. Int J Mol Sci. 2023 Mar 3; 24 (5) Epub 2023 Mar 03
   View PubMed
4. Li L, Sohn J, Genco RJ, Wactawski-Wende J, Goodison S, Diaz PI, Sun Y. Computational approach to modeling microbiome landscapes associated with chronic human disease progression. PLoS Comput Biol. 2022 Aug; 18 (8):e1010373 Epub 2022 Aug 04
   View PubMed
5. Chen R, Pagano I, Sun Y, Murakami K, Goodison S, Vairavan R, Tahsin M, Black PC, Rosser CJ, Furuya H. A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome. Diagnostics (Basel). 2022 Jul 25; 12 (8) Epub 2022 July 25
   View PubMed
6. Furuya H, Sasaki Y, Chen R, Peres R, Hokutan K, Murakami K, Kim N, Chan OTM, Pagano I, Dyrskjot L, Jensen JB, Malmstrom PU, Segersten U, Sun Y, Arab A, Goodarzi H, Goodison S, Rosser CJ. PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. Sci Rep. 2022 Jul 16; 12 (1):12186 Epub 2022 July 16
   View PubMed
7. Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark. 2022; 33 (1):151-157
   View PubMed
8. Chen J, Yang L, Li L, Goodison S, Sun Y. Alignment-free comparison of metagenomics sequences via approximate string matching. Bioinform Adv. 2022; 2 (1):vbac077 Epub 2022 Oct 21
   View PubMed
9. Murakami K, Pagano I, Chen R, Sun Y, Goodison S, Rosser CJ, Furuya H. Influencing Factors on the Oncuria Urinalysis Assay: An Experimental Model. Diagnostics (Basel). 2021 Jun 3; 11 (6) Epub 2021 June 03
   View PubMed
10. Hirasawa Y, Pagano I, Chen R, Sun Y, Dai Y, Gupta A, Tikhonenkov S, Goodison S, Rosser CJ, Furuya H. Diagnostic performance of Oncuria, a urinalysis test for bladder cancer. J Transl Med. 2021 Apr 6; 19 (1):141 Epub 2021 Apr 06
    View PubMed
11. Yang L, Chen R, Goodison S, Sun Y. An efficient and effective method to identify significantly perturbed subnetworks in cancer. Nat Comput Sci. 2021 Jan; 1 (1):79-88 Epub 2021 Jan 14
    View PubMed
12. Ogony JW, Radisky DC, Ruddy KJ, Goodison S, Wickland DP, Egan KM, Knutson KL, Asmann YW, Sherman ME. Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. Cancer Prev Res (Phila). 2020 Nov; 13 (11):901-910 Epub 2020 Aug 04
    View PubMed
13. Goodison S, Sherman ME, Sun Y. Computational disease progression modeling can provide insights into cancer evolution. Oncoscience. 2020 Mar; 7 (3-4):21-22 Epub 2020 May 01
    View PubMed
14. Chen R, Yang L, Goodison S, Sun Y. Deep-learning approach to identifying cancer subtypes using high-dimensional genomic data. Bioinformatics. 2020 Mar 1; 36 (5):1476-1483
    View PubMed
15. Chen R, Goodison S, Sun Y. Molecular Profiles of Matched Primary and Metastatic Tumor Samples Support a Linear Evolutionary Model of Breast Cancer. Cancer Res. 2020 Jan 15; 80 (2):170-174 Epub 2019 Nov 19
    View PubMed
16. Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser. Monoclonal antibody against CXCL1 (HL2401) as a novel agent in suppressing IL6 expression and tumoral growth Theranostics. 2019; 9((3)):853-867.
    
17. Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T. Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. Oncotarget. 2018 Jan 23; 9 (6):7101-7111 Epub 2018 Jan 03
    View PubMed
18. Shimizu Y, Furuya H, Tamashiro PM, Iino K, Chan OTM, Goodison S, Pagano I, Hokutan K, Peres R, Loo LWM, Hernandez B, Naing A, Chong CDK, Rosser CJ, Kawamori T. Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model. Carcinogenesis. 2018 Jan 12; 39 (1):47-55
    View PubMed
19. Wang Y, Goodison S, Li X, Hu H. Prognostic cancer gene signatures share common regulatory motifs. Sci Rep. 2017 Jul 6; 7 (1):4750 Epub 2017 July 06
    View PubMed
20. Sun Y, Yao J, Yang L, Chen R, Nowak NJ, Goodison S. Computational approach for deriving cancer progression roadmaps from static sample data. Nucleic Acids Res. 2017 May 19; 45 (9):e69
    View PubMed
21. Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Oncotarget. 2017 Feb 28; 8 (9):14593-14603
    View PubMed
22. Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, Goodison S. A microRNA biomarker panel for the non-invasive detection of bladder cancer. Oncotarget. 2016 Dec 27; 7 (52):86290-86299
    View PubMed
23. Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, Rosser CJ. A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. J Transl Med. 2016 Oct 7; 14 (1):287 Epub 2016 Oct 07
    View PubMed
24. Huang S, Kou L, Furuya H, Yu C, Goodison S, Kattan MW, Garmire L, Rosser CJ. A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Sep; 25 (9):1361-6 Epub 2016 July 06
    View PubMed
25. Urquidi V, Netherton M, Gomes-Giacoia E, Serie D, Eckel-Passow J, Rosser CJ, Goodison S. Urinary mRNA biomarker panel for the detection of urothelial carcinoma. Oncotarget. 2016 Jun 21; 7 (25):38731-38740
    View PubMed
26. Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist MD, Goodison S, Rosser CJ. A multiplex immunoassay for the non-invasive detection of bladder cancer. J Transl Med. 2016 Jan 30; 14:31
    View PubMed
27. Yao J, Mao Q, Mai V, Wang L, Goodison S, Sun Y. Feature Selection for Unsupervised Learning through Local Learning Pattern Recognition Letters. 2015; 53:100-107.
    
28. Sun Y, Yao J, Goodison S. Feature selection for nonlinear regression and its application to cancer research SIAM International Conference on Data Mining 2015, SDM 2015. 2015; 73-81.
    
29. Mao Q, Yang L, Wang L, Goodison S, Sun Y. SimplePPT: A simple principal tree algorithm SIAM International Conference on Data Mining 2015, SDM 2015. 2015; 792-800.
    
30. Mao Q, Wang L, Goodison S, Sun Y. Dimensionality reduction via graph structure learning Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2015; 2015-August:765-74.
    
31. Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ. Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagn Pathol. 2014 Nov 12; 9:200
    View PubMed
32. Chen LM, Chang M, Dai Y, Chai KX, Dyrskjot L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev. 2014 Sep; 23 (9):1804-12 Epub 2014 June 11
    View PubMed
33. Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23 (7):1340-5 Epub 2014 Apr 08
    View PubMed
34. Miyake M, Lawton A, Dai YF, Chang M, Mengual L, Alcaraz A, Goodison S, Rosser CJ. Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer. 2014 Feb 13; 14:86.
    View PubMed
35. Sun YJ, Yao J, Nowak NJ, Goodison S. Cancer progression modeling using static sample data. Genome Biol. 2014; 15(8):440.
    View PubMed
36. Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer. 2014; 14(1):310.
    View PubMed
37. Popescu NC, Goodison S. Deleted in liver cancer-1 (DLC1): An emerging metastasis suppressor gene. Molecular Diagnosis and Therapy. 2014; 18(3):293-302.
    View PubMed
38. Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S. Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnology. 2014; 14:24.
    View PubMed
39. Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ. PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res. 2014; 12(3):322-34.
    View PubMed
40. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One. 2014; 9 (6):e96705 Epub 2014 June 04
    View PubMed
41. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol. 2013 Dec; 190(6):2257-62. Epub 2013 Jun 11.
    View PubMed
42. Rosser CJ, Urquidi V, Goodison S. Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med. 2013 Oct; 7(5):779-90.
    View PubMed
43. Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Giacoia EG, Goodison S, Rosser CJ. Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urol. 2013 Sep 5; 13(1):42.
    
44. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol. 2013 Sep; 6(1):65.
    
45. Goodison S, Urquidi V, Kumar D, Reyes L, Rosser CJ. Complete Genome Sequence of Mycoplasma hyorhinis Strain SK76. Genome Announc. 2013; 1(1):e00101-12.
    
46. Goodison S, Rosser CJ, Urquidi V. Bladder Cancer Detection and Monitoring: Assessment of Urine- and Blood-based Marker Tests. Mol Diagn Ther. 2013; 17(2):71-84.
    
47. Urquidi V, Rosser CJ, Goodison S. Multiplex urinary tests for bladder cancer diagnosis. Eur Med J Urol. 2013; 1:70-73.
    
48. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest. 2013; 93(7):768-78.
    
49. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ. Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer. 2013; 13:322-28.
    
50. Rizwani W, Reyes L, Kim J, Goodison S, Rosser CJ. MG289 in Mycoplasma genitalium enhances microbial invasion and bacterial persistence in benign human prostate cells. Open Journal of Urology. 2013; 3:232-45.
    
51. Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013; 12(12):2697-708.
    
52. Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan L, Zawia NH, Lichtenberger LM, Basha R. Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation. Cell Physiol Biochem. 2013; 32(3):675-86. Epub 2013 Sep 10.
    View PubMed
53. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol. 2012 Dec; 188(6):2377-83. Epub 2012 Oct 22
    View PubMed
54. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. VEGF, CA9 and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urol. 2012; 79(5):1185.e1-6.
    
55. Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W. A Novel Aptamer Developed for Breast Cancer Cell Internalization. ChemMedChem. 2012; 7(1):79-84.
    
56. Urquidi V, Rosser CJ, Goodison S. Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis. Curr Med Chem. 2012; 19(22):3653-63.
    
57. Watanabe T, Hashimoto T, Sugino T, Soeda S, Nishiyama H, Morimura Y, Yamada H, Goodison S, Fujimori K. Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination. J Ovarian Res. 2012; 5:7-20.
    
58. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer. PLoS One. 2012; 7(5):e37797.
    
59. Urquidi V, Chang M, Dai Y, Kim J, Goodison S, Rosser CJ. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urology. 2012; 12:12-18.
    
60. Karhemo P-R, Ravela S, Ritamo I, Laakso M, Goodison S, Stenman U-H, Valmu L, Laakkonen P. An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis. J Proteomics. 2012; 77:87-100.
    
61. Miyake M, Goodison S, Gomes Giacoia E, Rizwani W, Ross, S, Rosser CJ. Urinary BTA: Indicator of Bladder Cancer or of Hematuria. World J Urol. 2012; 30(6):869-73.
    
62. Miyake M, Goodison S, Gomes Giacoia E, Rizwani W, Ross, S, Rosser CJ. Influencing factors on the NMP-22 urinalysis assay: an experimental model. BMC Urology. 2012; 12(1):23.
    
63. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(12):2149-58.
    
64. Goodison S, Kim J, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One. 2012; 7(10):e47469.
    
65. Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomark Med. 2012; 6(5):629-32.
    
66. Sankpal UT, Goodison S, Abdelrahim M, Basha R. Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem. 2011 Sep; 7(5):518-25.
    View PubMed
67. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol. 2011 Jul-Aug; 29(4):421-9. Epub 2009 Jul 03.
    View PubMed
68. Sippel KH, Venakatakrishnan B, Boehlein SK, Sankaran B, Quirit J, Govindasamy L, Agbandje-McKenna M, Goodison S, Rosser CJ, McKenna R. Insights into mycoplasma genitalium metabolism revealed by the structure of MG289, an extracytoplasmic thiamine binding lipoprotein. Proteins. 2011; 79(2):528-36.
    
69. Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M, Mercola D. Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma. Cancer Res. 2011; 71(7):2476-2487.
    
70. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S. Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection using LC-MS/MS and Label-free Quantification. Clin Cancer Res. 2011; 17(10):3349-59.
    
71. Huo Q, Colon J, Cordero A, Bogdanovic J, Baker CH, Goodison S, Pensky MY. A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnol. 2011; 9:20-32.
    
72. Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, Rosser CJ. Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostatecancer. BMC Cancer. 2011; 11:233-240.
    
73. Lee CY, Marzan D, Goodison S, Silletti S. α2-integrin-dependent suppression of pancreatic adenocarcinoma cell invasion involves ectodomain regulation of kalliekrien-related peptidases. J Oncol. 2011; 2011:365651, 1155-70.
    
74. Rosser CJ, Goodison S. Today's discoveries to tomorrow's care: cancer biomarkers revisited. Foreword. Biomark Med. 2010 Aug; 4(4):491-3.
    View PubMed
75. Sun Y, Urquidi Y, Goodison S. Predicting Breast Cancer Metastasis by Integrating Both Clinical and Genetic Markers. Breast Cancer Research and Treatment. 2010; 119(3):593-9.
    
76. Sun Y, Sinisa T, Goodison S. Local Learning Based Feature Selection for High Dimensional Data Analysis. IEEE Trans on Pattern Analysis and Machine Intelligence. 2010; 32(9):1610-26.
    
77. Xie X, Feng S, Vuong H, Liu Y, Goodison S, Lubman DM. A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach. Electrophoresis. 2010; 31(11):1842-1852.
    
78. Cai Y, Sun Y, Cheng Y, Li J, Goodison S. Fast Implementation of ℓ1 Regularized Learning Algorithms Using Gradient Descent Methods. SIAM Data Mining. 2010; 2010:862-871.
    
79. Goodison S, Sun Y, Urquidi V. Derivation of Cancer diagnostic and prognostic sfrom Gene Expression Data. Bioanalysis. 2010; 2(5):855-862.
    
80. Sun Y, Cai Y, Mai V, Farmerie W, Yu F, Goodison S. Advanced Computational Algorithm for Microbial Community Analysis Using Massive 16S rRNA Sequence Data. Nucleic Acids Research. 2010; 38(22):e205-215.
    
81. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009 Sep 15; 69(13):1460-9.
    View PubMed
82. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate. 2009 Jul 1; 69(10):1119-27.
    View PubMed
83. Sippel KH, Robbins AH, Reutzel R, Boehlein SK, Namiki K, Goodison S, Agbandje-McKenna M, Rosser CJ, McKenna R. Structural insights into the extracytoplasmic thiamine-binding lipoprotein p37 of Mycoplasma hyorhinis. J Bacteriol. 2009 Apr; 191(8):2585-92. Epub 2009 Feb 20.
    View PubMed
84. Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, Rosser CJ. Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate. 2009 Apr 1; 69(5):459-70.
    View PubMed
85. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):444-53. Epub 2009 Feb 03.
    View PubMed
86. Koziol JA, Feng AC, Jia Z, Wang Y, Goodison S, McClelland M, Mercola D. The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis. Bioinformatics. 2009 Jan 1; 25(1):54-60. Epub 2008 Jul 15.
    View PubMed
87. Cai Y, Sun Y, Li J, Goodison S. Online Feature Selection Algorithm with Bayesian ℓ1 Regularization. Proceedings 13th Pacific-Asia Conference on Knowledge Discovery and Data Mining. 2009; 2009:401-413.
    
88. Eiseler T, Döppler H, Yan IK, Goodison S, Storz P. Protein Kinase D1 mediates the breast cancer cell invasive phenotype. Breast Cancer Res. 2009; 11(1):R13.
    
89. Sakai Y, Goodison S, Cao W, Namiki K, Porvasnik S, Rosser CJ. VEGF treatment of microvascular endothelial cells induces Bcl-2 expression and multiple signaling factors. World J Urol. 2009; 27(5):659-66.
    
90. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine Based Assays for the Detection of Bladder Cancer. Biomark Med. 2009; 3(3):265-274.
    
91. Feng S, Yang N, Pennathur S, Goodison S, Lubman DM. Enrichment of Glycoproteins using Nano-scale Chelating Con A Monolithic Capillary Chromatography. Anal Chem. 2009; 81(10):3776-83.
    
92. Namiki K, Goodison S, Porvasnik S, Allan RW, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009; 4(9):e6872.
    
93. Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for bladder cancer detection. Expert Rev Proteomics. 2009; 6(5):507-14.
    
94. Layton T, Stalens C, Gunderson F, Goodison S, Silletti S. Syk Tyrosine Kinase Acts as a Pancreatic Adenocarcinoma Tumor Suppressor by Regulating Cellular Growth and Invasion. Am J Pathol. 2009; 175(6):2625-36.
    
95. Bandyopadhyay N, Kahveci T, Ranka S, Sun Y, Goodison S. Pathway based Feature Selection Algorithm for Cancer Microarray Data. Advances in Bioinformatics. 2009; 2009:Article ID 532989.
    
96. Eiseler T, Doppler H, Yan IK, Goodison S, Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res. 2009; 11 (1):R13 Epub 2009 Feb 25
    View PubMed
97. Wang Y, Ao X, Vuong H, Konanur M, Miller FR, Goodison S, Lubman DM. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res. 2008 Oct; 7(10):4313-25. Epub 2008 Aug 27.
    View PubMed
98. Goodison S, Urquidi V. Breast tumor metastasis: analysis via proteomic profiling. Expert Rev Proteomics. 2008 Jun; 5(3):457-67.
    View PubMed
99. Shuja S, Mohammadi A, Grigorian S, Goodison S. Patterns of Cathepsin H Expression in Glioblastoma Multiforme. The Internet Journal of Pathology. 2008; 7(1).
    
100. Sun Y, Todorovic S, Goodison S. A Feature Selection Algorithm Capable of Handling Extremely Large Data Dimensionality. Proceedings of the International Conference on Data Mining. 2008; 2008:530-541.
     
101. Sun Y, Goodison S. Combining Nomogram and Microarray Data for Predicting Prostate Cancer Recurrence. Proceedings of the 8th IEEE International Conference on BioInformatics and BioEngineering. 2008; 2008:1-7.
     
102. Patwa TH, Wang Y, Miller FR, Goodison S, Pennathur S, Barder TJ, Lubman DM. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin Appl. 2008; 3(1):51-66.
     
103. Sugino T, Yamaguchi T, Hoshi N, Kusakabe T, Ogura G, Goodison S, Suzuki T. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin Exp Metastasis. 2008; 25(7):835-41. Epub 2008 Aug 20
     View PubMed
104. Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD, Rosser CJ. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology. 2007 Oct; 70(4):832-7.
     View PubMed
105. Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics. 2007 Sep-Oct; 4(5):329-39.
     View PubMed
106. Anai S, Brown BD, Nakamura K, Goodison S, Hirao Y, Rosser CJ. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1161-8.
     View PubMed
107. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res. 2007 Jul; 6(7):2631-9. Epub 2007 May 23.
     View PubMed
108. Sugino T, Yamaguchi T, Ogura G, Kusakabe T, Goodison S, Homma Y, Suzuki T. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol. 2007 Jun; 212(2):152-60.
     View PubMed
109. Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, Goodison S, Mizokami A, Rosser CJ. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J Urol. 2007 May; 177(5):1913-7.
     View PubMed
110. Rice L, Handayani R, Cui Y, Medrano T, Samedi V, Baker H, Szabo NJ, Rosser CJ, Goodison S, Shiverick KT. Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. J Nutr. 2007 Apr; 137(4):964-72.
     View PubMed
111. Ranki T, Kanerva A, Ristimäki A, Hakkarainen T, Sarkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S, Hemminki A. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer. Gene Therapy. 2007; 14(1):58-67.
     
112. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic Markers. Bioinformatics. 2007; 23(1):30-7.
     
113. Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics. 2007 Jan; 7(2):299-312.
     View PubMed
114. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther. 2007 Jan; 6(1):101-11.
     View PubMed
115. Goodison S, Nakamura K, Iczkowski KA, Anai S, Boehlein SK, Rosser CJ. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenet Genome Res. 2007; 118(2-4):204-13.
     View PubMed
116. Urquidi V, Goodison S. Genomic signatures of breast cancer metastasis. Cytogenet Genome Res. 2007; 118(2-4):116-29.
     View PubMed
117. Sun Y, Goodison S. Predicting Breast Cancer Metastasis by Integrating Both Clinical and Genetic Markers. Proceedings International Conference on Bioinformatics and Computational Biology. 2007; 1:229-235.
     
118. Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, Rosser CJ. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther. 2006 Oct; 17(10):975-84.
     View PubMed
119. Khalbuss WE, Ambaye A, Goodison S, Loya A, Masood S. Papillary carcinoma of the breast in a male patient with a treated prostatic carcinoma diagnosed by fine-needle aspiration biopsy: a case report and review of the literature. Diagn Cytopathol. 2006 Mar; 34(3):214-7.
     View PubMed
120. Khalbuss W. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. Cytojournal. 2006; 3:18. Epub 2006 Aug 10
     View PubMed
121. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, Urquidi V. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005 Jul 15; 65(14):6042-53.
     View PubMed
122. Goodison S, Viars C, Urquidi V. Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genet Cytogenet. 2005 Jan 1; 156(1):37-48.
     View PubMed
123. Kreunin P, Urquidi V, Lubman DM, Goodison S. Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics. 2004 Sep; 4(9):2754-65.
     View PubMed
124. Sugino T, Yamaguchi T, Ogura G, Saito A, Hashimoto T, Hoshi N, Yoshida S, Goodison S, Suzuki T. Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med. 2004 Apr 5; 2:9. [Epub ahead of print]
     View PubMed
125. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, Klacansky I, Masys D, Arden K, Goodison S, McClelland M, Wang Y, Sawyers A, Kalcheva I, Tarin D, Mercola D. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):615-20.
     View PubMed
126. Sloan DD, Nicholson B, Urquidi V, Goodison S. Detection of differentially expressed genes in an isogenic breast metastasis model using RNA arbitrarily primed-polymerase chain reaction coupled with array hybridization (RAP-array). Am J Pathol. 2004 Jan; 164(1):315-23.
     View PubMed
127. Bertholf RL, Goodison S. Television viewing and attention deficits in children. Pediatrics. 2004; 114(2):511-2.
     
128. Goodison S, Viars C, Grazzini M, Urquidi V. The interrelationship between DRIM gene expression and cytogenetic and phenotypic characteristics in human breast tumor cell lines. BMC Genomics. 2003 Sep 22; 4(1):39.
     View PubMed
129. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, Urquidi V, Hoffman RM, Tarin D. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1):3808-14.
     View PubMed
130. Ma H, Urquidi V, Wong J, Kleeman J, Goodison S. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells. Mol Cancer Res. 2003 Aug; 1(10):739-46.
     View PubMed
131. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V. Representational Difference Analysis Reveals a Correlation between MMP8 Expression and Breast Cancer Metastasis. Differentiation. 2003; 71(2):114-25.
     
132. Hayashi K, Goodison S, Urquidi V, Tarin D, Lotan R, Tahara E. The effects of all-trans retinoic acid on the growth of matched metastatic and non-metastatic breast cancer cell lines. Int J Oncol. 2003; 22(3):623-629.
     
133. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 2003; 5(5):R136-43. Epub 2003 Jul 09.
     View PubMed
134. Kawai K, Viars C, Arden K, Tarin D, Urquidi V, Goodison S. Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line. Genes Chromosomes Cancer. 2002 May; 34(1):1-8.
     View PubMed
135. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res. 2002 Jan; 8(1):61-74.
     View PubMed
136. Sugino T, Kusakabe T, Hoshi N, Yamaguchi T, Goodison S, Sekimata M, Homma Y, Suzuki T. An invasion-independent pathway of blood-borne dissemination : A new murine mammary tumor model of metastasis. Am J Pathol. 2002; 160(6):1973-1980.
     
137. Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara E. Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation. 2001 Aug; 68(1):13-21.
     View PubMed
138. Taniyama K, Goodison S, Ito R, Bookstein R, Miyoshi N, Tahara E, Tarin D, Urquidi V. PTEN expression is maintained in sporadic colorectal tumours. J Pathol. 2001 Jul; 194(3):341-8.
     View PubMed
139. Aogi K, Woodman A, Urquidi V, Mangham DC, Tarin D, Goodison S. Telomerase activity in soft-tissue and bone sarcomas. Clin Cancer Res. 2000 Dec; 6(12):4776-81.
     View PubMed
140. Woodman AC, Goodison S, Drake M, Noble J, Tarin D. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia. Clin Cancer Res. 2000 Jun; 6(6):2381-92.
     View PubMed
141. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu Rev Med. 2000; 51:65-79.
     View PubMed
142. Aogi K, Kitahara K, Urquidi V, Tarin D, Goodison S. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid. Clin Cancer Res. 1999 Oct; 5(10):2790-7.
     View PubMed
143. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999 Aug; 52(4):189-96.
     View PubMed
144. Gorham H, Woodman A, Goodison S, Marsh J, Charnock M, Manek S, Sugino T, Tarin D. CD44 expression in cervical intraepithelial neoplasia (CIN) and carcinoma. Mol Diagn. 1999 Mar; 4(1):45-56.
     View PubMed
145. Urquidi V, Tarin D, Goodison S. Telomerase in cancer: clinical applications. Ann Med. 1998 Oct; 30(5):419-30.
     View PubMed
146. Goodison S, Yoshida K, Churchman M, Tarin D. Multiple intron retention occurs in tumor cell CD44 mRNA processing. Am J Pathol. 1998 Oct; 153(4):1221-8.
     View PubMed
147. Sugino T, Yoshida K, Zhao S, Goodison S, Tarin D. Disorderly CD44 gene expression in human cancer cells can be modulated by growth conditions. J Pathol. 1998 Sep; 186(1):17-23.
     View PubMed
148. Aogi K, Kitahara K, Buley I, Backdahl M, Tahara H, Sugino T, Tarin D, Goodison S. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res. 1998 Aug; 4(8):1965-70.
     View PubMed
149. Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci. 1998 Jul 01; 3:e89-109.
     View PubMed
150. Goodison S, Tarin D. Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology. 1998 Jan; 32(1):1-6.
     View PubMed
151. Sugino T, Yoshida K, Bolodeoku J, Tarin D, Goodison S. Telomerase activity and its inhibition in benign and malignant breast lesions. J Pathol. 1997 Sep; 183(1):57-61.
     View PubMed
152. Goodison S, Yoshida K, Sugino T, Woodman A, Gorham H, Bolodeoku J, Kaufmann M, Tarin D. Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors. Cancer Res. 1997 Aug 1; 57(15):3140-4.
     View PubMed
153. Gorham H, Yoshida K, Sugino T, Marsh G, Manek S, Charnock M, Tarin D, Goodison S. Telomerase activity in human gynaecological malignancies. J Clin Pathol. 1997 Jun; 50(6):501-4.
     View PubMed
154. Bolodeoku J, Yoshida K, Sugino T, Churchman M, Woodman A, Goodison S, Tarin D. CD44 expression in human breast cancer cell lines is related to oestrogen receptor (ER) status and confluency in vitro. Biochem Soc Trans. 1997 May; 25(2):356S.
     View PubMed
155. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, Fellows G, Goodison S, Tahara E, Tarin D. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer. 1997 Jan 15; 79(2):362-9.
     View PubMed
156. Yoshida K, Sugino T, Goodison S, Warren BF, Nolan D, Wadsworth S, Mortensen NJ, Toge T, Tahara E, Tarin D. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer. 1997; 75(4):548-53.
     View PubMed
157. Goodison S, Ashcroft SJ. Trans-acting factor(s) confer glucose-responsive transcriptional regulation in the insulin gene. Adv Exp Med Biol. 1997; 426:97-100.
     View PubMed
158. Woodman AC, Sugiyama M, Yoshida K, Sugino T, Borgya A, Goodison S, Matsumura Y, Tarin D. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol. 1996 Nov; 149(5):1519-30.
     View PubMed
159. Yoshida K, Goodison S, Sugino T, Bolodeoku J, Churchman M, Warren BF, Tarin D. Semiquantitative Detection of Abnormal CD44 Transcripts in Colon Carcinomas by Reverse Transcription-Polymerase Chain Reaction Enzyme-linked Immunosorbant Assay (RT-PCR ELISA). Mol Diagn. 1996 Sep; 1(3):167-73.
     View PubMed
160. Bolodeoku J, Yoshida K, Sugino T, Goodison S, Tarin D. Accumulation of Immature Intron-containing CD44 Gene Transcripts in Breast Cancer Tissues. Mol Diagn. 1996 Sep; 1(3):175-81.
     View PubMed
161. Sugino T, Yoshida K, Bolodeoku J, Tahara H, Buley I, Manek S, Wells C, Goodison S, Ide T, Suzuki T, Tahara E, Tarin D. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int J Cancer. 1996 Aug 22; 69(4):301-6.
     View PubMed
162. Gorham H, Sugino T, Bolodeoku J, Yoshida K, Goodison S, Tarin D. Distribution of CD44 messenger RNA in archival paraffin wax embedded tumours and normal tissues viewed by in situ hybridisation. Clin Mol Pathol. 1996 Jun; 49(3):M147-50.
     View PubMed
163. Yoshida K, Sugino T, Bolodeoku J, Warren BF, Goodison S, Woodman A, Toge T, Tahara E, Tarin D. Detection of exfoliated carcinoma cells in colonic luminal washings by identification of deranged patterns of expression of the CD44 gene. J Clin Pathol. 1996 Apr; 49(4):300-5.
     View PubMed
164. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996; 149:873-882.
     
165. Yoshida K, Bolodeoku J, Sugino T, Goodison S, Matsumura Y, Warren BF, Toge T, Tahara E, Tarin D. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res. 1995 Oct 1; 55(19):4273-7.
     View PubMed
166. Goodison S, Miyazaki J, Ashcroft SJ. Response to glucose of transcription factor binding to the rat insulin-1 gene promoter. Biochem Biophys Res Commun. 1994 Aug 30; 203(1):702-10.
     View PubMed
167. Goodison S, Ashcroft SJ. Human insulin promoter driven reporter gene expression. Biochem Soc Trans. 1993 Feb; 21(1):22S.
     View PubMed
168. Goodison S, Kenna S, Ashcroft SJH. Control of insulin gene expression by glucose. Biochem J. 1992; 285:563-568.
     
169. Goodison S, Ashcroft SJH. Comparison of rat-I and human insulin gene 5' sequence-mediated transcriptional responses. Diabetic Medicine. 1992; 9:512-514.